OTCMKTS:ENZNEnzon Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enzon Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.23 +0.03 (+15.25 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$0.20Now: $0.23▼$0.2450-Day Range$0.16MA: $0.17▼$0.2052-Week Range$0.14Now: $0.23▼$0.31Volume183,817 shsAverage Volume70,832 shsMarket CapitalizationN/AP/E Ratio1.43Dividend YieldN/ABeta0.17 ProfileAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Enzon Pharmaceuticals. Previous Next 2.8 Community Rank Outperform VotesEnzon Pharmaceuticals has received 107 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEnzon Pharmaceuticals has received 83 “underperform” votes. (Add your “underperform” vote.)Community SentimentEnzon Pharmaceuticals has received 56.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENZN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEnzon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnzon Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enzon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.06% of the stock of Enzon Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.02% of the stock of Enzon Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Enzon Pharmaceuticals is 1.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Enzon Pharmaceuticals is 1.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 16.08.Price to Book Value per Share RatioEnzon Pharmaceuticals has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.81 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CUSIP29390410 CIK727510 Webwww.enzon.com Phone732-980-4500Debt Debt-to-Equity RatioN/A Current Ratio14.06 Quick Ratio14.06Price-To-Earnings Trailing P/E Ratio1.43 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$210,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book1.65Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-980,000.00 Net Margins-1,745.90% Return on Equity-17.93% Return on Assets-13.84%Miscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $0.23 +0.03 (+15.25 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ENZN News and Ratings via Email Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter. Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ENZN stock has increased by 36.1% and is now trading at $0.2305. View which stocks have been most impacted by Coronavirus. When is Enzon Pharmaceuticals' next earnings date? Enzon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Enzon Pharmaceuticals. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) posted its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) EPS for the quarter. Enzon Pharmaceuticals had a negative return on equity of 17.93% and a negative net margin of 1,745.90%. View Enzon Pharmaceuticals' earnings history. Has Enzon Pharmaceuticals been receiving favorable news coverage? Press coverage about ENZN stock has trended very positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enzon Pharmaceuticals earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Enzon Pharmaceuticals. Who are some of Enzon Pharmaceuticals' key competitors? Some companies that are related to Enzon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), AEterna Zentaris (AEZS), CBL & Associates Properties (CBL), NGL Energy Partners (NGL), Pennsylvania R.E.I.T. (PEI), (CHK), Summit Midstream Partners (SMLP), Golar LNG Partners (GMLP) and Washington Prime Group (WPG). Who are Enzon Pharmaceuticals' key executives? Enzon Pharmaceuticals' management team includes the following people: Mr. Andrew Rackear, CEO & Sec. (Age 65)Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 76) What is Enzon Pharmaceuticals' stock symbol? Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN." How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Enzon Pharmaceuticals' stock price today? One share of ENZN stock can currently be purchased for approximately $0.23. What is Enzon Pharmaceuticals' official website? The official website for Enzon Pharmaceuticals is www.enzon.com. How can I contact Enzon Pharmaceuticals? Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
